A052020 Stock Overview
STCube, Inc., a biopharmaceutical company, develops medicines in South Korea.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
STCube, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩6,390.00 |
| 52 Week High | ₩21,050.00 |
| 52 Week Low | ₩4,350.00 |
| Beta | 0.044 |
| 1 Month Change | 21.25% |
| 3 Month Change | 7.40% |
| 1 Year Change | -64.50% |
| 3 Year Change | -24.82% |
| 5 Year Change | -66.72% |
| Change since IPO | 50.35% |
Recent News & Updates
Shareholder Returns
| A052020 | KR Electronic | KR Market | |
|---|---|---|---|
| 7D | 23.1% | 5.2% | 2.1% |
| 1Y | -64.5% | -16.4% | 6.6% |
Return vs Industry: A052020 underperformed the KR Electronic industry which returned -16.4% over the past year.
Return vs Market: A052020 underperformed the KR Market which returned 6.6% over the past year.
Price Volatility
| A052020 volatility | |
|---|---|
| A052020 Average Weekly Movement | 14.2% |
| Electronic Industry Average Movement | 5.6% |
| Market Average Movement | 5.1% |
| 10% most volatile stocks in KR Market | 11.8% |
| 10% least volatile stocks in KR Market | 2.3% |
Stable Share Price: A052020's share price has been volatile over the past 3 months.
Volatility Over Time: A052020's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of KR stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1989 | 13 | Hyunjin Jung | www.stcube.com |
STCube, Inc., a biopharmaceutical company, develops medicines in South Korea. The company develops anti-cancer immunotherapeutic drugs and anti-viral drugs. It offers platform technologies, which include In vivo RNAi ICP target discovery platform for exploring material ICP target; glycosylation-specific antibody development platform for development of antibodies that mask glycosylation sites on target proteins; and ICP functional assay platform for development of various in vivo/in vitro analytical/experimental methods.
STCube, Inc. Fundamentals Summary
| A052020 fundamental statistics | |
|---|---|
| Market cap | ₩300.05b |
| Earnings (TTM) | -₩24.50b |
| Revenue (TTM) | ₩5.83b |
51.5x
P/S Ratio-12.2x
P/E RatioIs A052020 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A052020 income statement (TTM) | |
|---|---|
| Revenue | ₩5.83b |
| Cost of Revenue | ₩5.69b |
| Gross Profit | ₩140.18m |
| Other Expenses | ₩24.64b |
| Earnings | -₩24.50b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -521.84 |
| Gross Margin | 2.41% |
| Net Profit Margin | -420.51% |
| Debt/Equity Ratio | 0% |
How did A052020 perform over the long term?
See historical performance and comparison